Stem definition | Drug id | CAS RN |
---|---|---|
diagnostic agents, gadolinium derivatives | 4494 | 131410-48-5 |
Molecule | Description |
---|---|
Synonyms:
|
for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions
|
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.79 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.46 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 8, 1993 | FDA | GE HEALTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrogenic systemic fibrosis | 2221.55 | 55.36 | 349 | 2613 | 4116 | 56284989 |
Skin hypertrophy | 407.91 | 55.36 | 79 | 2883 | 3131 | 56285974 |
Skin induration | 406.54 | 55.36 | 78 | 2884 | 2940 | 56286165 |
Skin tightness | 309.29 | 55.36 | 65 | 2897 | 3890 | 56285215 |
Fibrosis | 198.22 | 55.36 | 45 | 2917 | 3846 | 56285259 |
Skin fibrosis | 197.87 | 55.36 | 35 | 2927 | 829 | 56288276 |
Skin hyperpigmentation | 153.51 | 55.36 | 39 | 2923 | 5358 | 56283747 |
Joint range of motion decreased | 136.55 | 55.36 | 51 | 2911 | 25314 | 56263791 |
Joint contracture | 110.37 | 55.36 | 24 | 2938 | 1678 | 56287427 |
Scar | 105.14 | 55.36 | 35 | 2927 | 12398 | 56276707 |
Emotional distress | 94.70 | 55.36 | 41 | 2921 | 29722 | 56259383 |
Skin discolouration | 92.20 | 55.36 | 42 | 2920 | 34314 | 56254791 |
Anhedonia | 80.20 | 55.36 | 27 | 2935 | 9887 | 56279218 |
Peau d'orange | 76.28 | 55.36 | 12 | 2950 | 134 | 56288971 |
Joint stiffness | 72.65 | 55.36 | 36 | 2926 | 35389 | 56253716 |
Oedema peripheral | 70.99 | 55.36 | 64 | 2898 | 171190 | 56117915 |
Erythema | 70.05 | 55.36 | 61 | 2901 | 155878 | 56133227 |
Mobility decreased | 68.63 | 55.36 | 50 | 2912 | 98941 | 56190164 |
Skin plaque | 64.24 | 55.36 | 21 | 2941 | 7017 | 56282088 |
Muscle contracture | 61.21 | 55.36 | 14 | 2948 | 1230 | 56287875 |
Extremity contracture | 60.83 | 55.36 | 14 | 2948 | 1265 | 56287840 |
Deformity | 60.19 | 55.36 | 22 | 2940 | 10233 | 56278872 |
Pain | 59.37 | 55.36 | 116 | 2846 | 663068 | 55626037 |
Magnetic resonance imaging head abnormal | 55.87 | 55.36 | 14 | 2948 | 1812 | 56287293 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrogenic systemic fibrosis | 2296.10 | 53.98 | 386 | 2782 | 3569 | 31690607 |
Skin hypertrophy | 378.09 | 53.98 | 79 | 3089 | 2386 | 31691790 |
Skin tightness | 357.19 | 53.98 | 73 | 3095 | 1971 | 31692205 |
Skin induration | 356.55 | 53.98 | 73 | 3095 | 1989 | 31692187 |
Joint range of motion decreased | 238.71 | 53.98 | 66 | 3102 | 6595 | 31687581 |
Joint contracture | 237.51 | 53.98 | 51 | 3117 | 1752 | 31692424 |
Skin fibrosis | 217.60 | 53.98 | 43 | 3125 | 970 | 31693206 |
Fibrosis | 180.49 | 53.98 | 43 | 3125 | 2366 | 31691810 |
Scar | 167.19 | 53.98 | 48 | 3120 | 5482 | 31688694 |
Extremity contracture | 132.97 | 53.98 | 27 | 3141 | 700 | 31693476 |
Deformity | 128.61 | 53.98 | 30 | 3138 | 1503 | 31692673 |
Emotional distress | 125.80 | 53.98 | 49 | 3119 | 14307 | 31679869 |
Mobility decreased | 122.16 | 53.98 | 58 | 3110 | 27411 | 31666765 |
Joint stiffness | 112.45 | 53.98 | 41 | 3127 | 9980 | 31684196 |
Anhedonia | 104.60 | 53.98 | 36 | 3132 | 7406 | 31686770 |
Pain | 85.87 | 53.98 | 99 | 3069 | 186660 | 31507516 |
Oedema peripheral | 84.66 | 53.98 | 77 | 3091 | 109762 | 31584414 |
Injury | 82.64 | 53.98 | 40 | 3128 | 19669 | 31674507 |
Skin disorder | 70.47 | 53.98 | 31 | 3137 | 12250 | 31681926 |
Skin discolouration | 68.05 | 53.98 | 33 | 3135 | 16274 | 31677902 |
Skin hyperpigmentation | 64.56 | 53.98 | 20 | 3148 | 2951 | 31691225 |
Musculoskeletal stiffness | 64.48 | 53.98 | 44 | 3124 | 41281 | 31652895 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrogenic systemic fibrosis | 3114.19 | 52.88 | 503 | 4194 | 5549 | 70918198 |
Skin hypertrophy | 615.65 | 52.88 | 123 | 4574 | 4529 | 70919218 |
Skin induration | 589.03 | 52.88 | 117 | 4580 | 4178 | 70919569 |
Skin tightness | 528.30 | 52.88 | 110 | 4587 | 4980 | 70918767 |
Skin fibrosis | 319.68 | 52.88 | 59 | 4638 | 1406 | 70922341 |
Joint range of motion decreased | 276.52 | 52.88 | 92 | 4605 | 25934 | 70897813 |
Joint contracture | 268.62 | 52.88 | 55 | 4642 | 2277 | 70921470 |
Fibrosis | 243.54 | 52.88 | 58 | 4639 | 4836 | 70918911 |
Scar | 195.78 | 52.88 | 61 | 4636 | 13920 | 70909827 |
Biopsy brain abnormal | 174.34 | 52.88 | 21 | 4676 | 8 | 70923739 |
Skin hyperpigmentation | 172.72 | 52.88 | 47 | 4650 | 6668 | 70917079 |
Joint stiffness | 140.88 | 52.88 | 61 | 4636 | 35115 | 70888632 |
Oedema peripheral | 136.68 | 52.88 | 116 | 4581 | 227975 | 70695772 |
Emotional distress | 131.21 | 52.88 | 59 | 4638 | 37129 | 70886618 |
Skin discolouration | 131.00 | 52.88 | 59 | 4638 | 37266 | 70886481 |
Mobility decreased | 124.36 | 52.88 | 80 | 4617 | 102919 | 70820828 |
Anhedonia | 122.47 | 52.88 | 43 | 4654 | 14170 | 70909577 |
Extremity contracture | 116.30 | 52.88 | 26 | 4671 | 1634 | 70922113 |
Deformity | 115.25 | 52.88 | 36 | 4661 | 8261 | 70915486 |
Peau d'orange | 103.86 | 52.88 | 18 | 4679 | 295 | 70923452 |
Skin disorder | 100.21 | 52.88 | 46 | 4651 | 30311 | 70893436 |
Pain | 91.76 | 52.88 | 155 | 4542 | 628661 | 70295086 |
Erythema | 86.98 | 52.88 | 85 | 4612 | 199478 | 70724269 |
Muscle contracture | 83.64 | 52.88 | 21 | 4676 | 2173 | 70921574 |
Skin plaque | 81.97 | 52.88 | 29 | 4668 | 9754 | 70913993 |
Injury | 72.10 | 52.88 | 48 | 4649 | 65197 | 70858550 |
Musculoskeletal stiffness | 68.19 | 52.88 | 65 | 4632 | 147695 | 70776052 |
Magnetic resonance imaging head abnormal | 66.66 | 52.88 | 18 | 4679 | 2474 | 70921273 |
Pruritus | 63.67 | 52.88 | 95 | 4602 | 345465 | 70578282 |
Muscle tightness | 62.56 | 52.88 | 25 | 4672 | 11737 | 70912010 |
Skin exfoliation | 61.63 | 52.88 | 39 | 4658 | 48587 | 70875160 |
Anxiety | 59.49 | 52.88 | 73 | 4624 | 220257 | 70703490 |
Pain of skin | 58.73 | 52.88 | 23 | 4674 | 10243 | 70913504 |
Muscular weakness | 58.46 | 52.88 | 58 | 4639 | 138278 | 70785469 |
Magnetic resonance imaging abnormal | 57.78 | 52.88 | 17 | 4680 | 3183 | 70920564 |
Gait disturbance | 57.68 | 52.88 | 66 | 4631 | 185040 | 70738707 |
Dry skin | 54.30 | 52.88 | 38 | 4659 | 55893 | 70867854 |
None
Source | Code | Description |
---|---|---|
ATC | V08CA03 | VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media |
MeSH PA | D003287 | Contrast Media |
MeSH PA | D064907 | Diagnostic Uses of Chemicals |
FDA MoA | N0000175862 | Magnetic Resonance Contrast Activity |
FDA EPC | N0000180184 | Paramagnetic Contrast Agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Magnetic resonance imaging | indication | 113091000 |
None
None
None
None
None
None
ID | Source |
---|---|
D04284 | KEGG_DRUG |
4020689 | VUID |
N0000148302 | NUI |
4020689 | VANDF |
CHEBI:31642 | CHEBI |
CHEMBL1200346 | ChEMBL_ID |
C064925 | MESH_SUPPLEMENTAL_RECORD_UI |
6636 | INN_ID |
DB00225 | DRUGBANK_ID |
84F6U3J2R6 | UNII |
41144 | RXNORM |
10205 | MMSL |
4771 | MMSL |
d04083 | MMSL |
004259 | NDDF |
354088005 | SNOMEDCT_US |
396067007 | SNOMEDCT_US |
C0082646 | UMLSCUI |
153921 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0691 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |